Wednesday, February 6, 2013
Kineta Inc., of Seattle, and RLB Holdings formed a partnership to develop Kineta's drug candidates ShK-186 and rOAS. ShK-186 is in development or autoimmune disease, and rOAS is a candidate for viral illnesses.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.